A 28-year-old multigravida (G3P2) at 35 weeks + 4 days gestation is admitted with vaginal bleeding (approximately 300 mL) and mild lower abdominal discomfort. Vital signs: BP 110/70 mmHg, HR 92/min, RR 18/min. Fetal heart rate is 142/min with normal variability. Transabdominal ultrasound confirms partial placenta previa with the lower placental edge 1.5 cm from the internal cervical os. The patient has had two prior episodes of bleeding in the past 2 weeks, both self-limiting. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This is a **stable, hemodynamically compensated patient at 35 weeks with partial previa and recurrent but self-limiting bleeding**. The clinical picture calls for **planned preterm cesarean at 36–37 weeks** (not emergency delivery, not discharge). ## Decision Framework: When to Deliver in Placenta Previa ```mermaid flowchart TD A[Placenta Previa + Bleeding]:::outcome --> B{Maternal Hemodynamics?}:::decision B -->|Unstable: Hgb <7, SBP <90, ongoing hemorrhage| C[EMERGENCY Cesarean]:::urgent B -->|Stable| D{Gestational Age?}:::decision D -->|<34 weeks| E[Expectant Mgmt + Steroids]:::action D -->|34-36+6 weeks| F[Tocolytics + Plan Elective CS 36-37 wks]:::action D -->|≥37 weeks| G[Elective Cesarean]:::action F --> H[Antenatal Corticosteroids if <36 wks]:::action F --> I[Fetal Monitoring NST/CTG]:::action ``` ## Why Tocolytics + Planned Cesarean at 36–37 Weeks? **Key Point:** At 35+4 weeks with stable vitals and recurrent but non-massive bleeding, **tocolytics (nifedipine or terbutaline) suppress uterine contractions** and reduce further bleeding risk, allowing safe progression to 36–37 weeks when neonatal morbidity drops sharply. **High-Yield:** - **34–36 weeks:** Neonatal RDS risk ~10–15%; benefit of 1–2 weeks maturation is substantial. - **>36 weeks:** RDS risk <5%; neonatal outcomes approach term. - **Tocolytics** reduce bleeding-triggered labor and allow time for in-utero transfer if needed. **Clinical Pearl:** Recurrent bleeding in placenta previa (even if self-limiting) is a sign of **placental instability** and warrants **admission and planned delivery by 36–37 weeks**, not expectant management beyond this point. This patient is beyond the "expectant management" window (which typically extends to 34 weeks). ## Management at 35+4 Weeks with Recurrent Bleeding | Action | Rationale | |--------|----------| | **Admit** | Recurrent bleeding = high risk for massive hemorrhage | | **Tocolytics** (nifedipine 10 mg TDS or terbutaline 2.5 mg TDS) | Suppress contractions, reduce placental irritation and bleeding | | **Antenatal corticosteroids** (if not given) | Reduce neonatal RDS risk (benefit at 34–36 weeks is proven) | | **Fetal monitoring** (NST, CTG) | Ensure fetal well-being; guide timing of delivery | | **Plan elective cesarean at 36–37 weeks** | Balances neonatal maturity with bleeding risk | | **Keep IV access, cross-matched blood** | Emergency cesarean capability if uncontrolled bleeding | ## Why NOT the Other Options **Emergency cesarean now:** Patient is hemodynamically stable (BP 110/70, HR 92, Hgb likely adequate). Bleeding is recurrent but self-limiting, not massive. Delivering at 35+4 weeks exposes neonate to unnecessary prematurity (RDS, hypoglycemia, feeding difficulty). Emergency delivery is reserved for **uncontrolled hemorrhage, maternal shock, or fetal distress**. **Discharge home:** Dangerous. Recurrent bleeding in the setting of placenta previa signals high risk for massive hemorrhage. Patient requires hospitalization, monitoring, and immediate surgical access. Home management is not safe beyond 34 weeks in partial previa with bleeding. **Transvaginal ultrasound:** While transvaginal USS can refine diagnosis in uncertain cases, it is **relatively contraindicated in symptomatic placenta previa** (risk of triggering hemorrhage). Transabdominal USS has already confirmed partial previa; transvaginal exam adds little and carries risk. [cite:Williams Obstetrics 26e Ch 34; ACOG Practice Bulletin #183]